A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy

NCT00000909 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Aldesleukin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)